178 related articles for article (PubMed ID: 28939130)
81. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.
Woo EY; Yeh H; Chu CS; Schlienger K; Carroll RG; Riley JL; Kaiser LR; June CH
J Immunol; 2002 May; 168(9):4272-6. PubMed ID: 11970966
[TBL] [Abstract][Full Text] [Related]
82. Insufficient CD100 shedding contributes to suppression of CD8
Wang HM; Zhang XH; Ye LQ; Zhang K; Yang NN; Geng S; Chen J; Zhao SX; Yang KL; Fan FF
Immunology; 2020 Jun; 160(2):209-219. PubMed ID: 32149403
[TBL] [Abstract][Full Text] [Related]
83. Long-term prognostic significance of interleukin-17-producing T cells in patients with non-small cell lung cancer.
Song L; Ma S; Chen L; Miao L; Tao M; Liu H
Cancer Sci; 2019 Jul; 110(7):2100-2109. PubMed ID: 31100180
[TBL] [Abstract][Full Text] [Related]
84. Immunomodulatory effects of chemotherapy on blood lymphocytes and survival of patients with advanced non-small cell lung cancer.
Aldarouish M; Su X; Qiao J; Gao C; Chen Y; Dai A; Zhang T; Shu Y; Wang C
Int J Immunopathol Pharmacol; 2019; 33():2058738419839592. PubMed ID: 30968711
[TBL] [Abstract][Full Text] [Related]
85. Age-dependent changes in the expression of regulatory cell surface ligands in activated human T-cells.
Canaday DH; Parker KE; Aung H; Chen HE; Nunez-Medina D; Burant CJ
BMC Immunol; 2013 Oct; 14():45. PubMed ID: 24083425
[TBL] [Abstract][Full Text] [Related]
86. Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor.
Li P; Qin P; Fu X; Zhang G; Yan X; Zhang M; Zhang X; Yang J; Wang H; Ma Z
Ann Palliat Med; 2021 Mar; 10(3):3039-3049. PubMed ID: 33849094
[TBL] [Abstract][Full Text] [Related]
87. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma.
Hiraoka K; Miyamoto M; Cho Y; Suzuoki M; Oshikiri T; Nakakubo Y; Itoh T; Ohbuchi T; Kondo S; Katoh H
Br J Cancer; 2006 Jan; 94(2):275-80. PubMed ID: 16421594
[TBL] [Abstract][Full Text] [Related]
88. CD4+CD25high regulatory cells in peripheral blood of NSCLC patients.
Liu L; Yao J; Ding Q; Huang S
J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):548-51. PubMed ID: 17219964
[TBL] [Abstract][Full Text] [Related]
89. Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.
Mark NM; Kargl J; Busch SE; Yang GHY; Metz HE; Zhang H; Hubbard JJ; Pipavath SNJ; Madtes DK; Houghton AM
Am J Respir Crit Care Med; 2018 Feb; 197(3):325-336. PubMed ID: 28934595
[TBL] [Abstract][Full Text] [Related]
90. Analysis of non-small cell lung cancer microenvironment indicates preponderance of T cell exhaustion marker expression.
Zhou H; Liu T; Wang Z
Exp Cell Res; 2017 Nov; 360(2):205-209. PubMed ID: 28890294
[TBL] [Abstract][Full Text] [Related]
91. Assessment of local cellular immunity in lung cancer by bronchoalveolar lavage.
Lorenz J; Müller-Quernheim J; Castillo-Höfer C; Doboszỳnska A; Ferlinz R
Klin Wochenschr; 1990 Jul; 68(14):728-34. PubMed ID: 1975283
[TBL] [Abstract][Full Text] [Related]
92. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer.
Waki K; Yamada T; Yoshiyama K; Terazaki Y; Sakamoto S; Matsueda S; Komatsu N; Sugawara S; Takamori S; Itoh K; Yamada A
Cancer Sci; 2014 Oct; 105(10):1229-35. PubMed ID: 25117757
[TBL] [Abstract][Full Text] [Related]
93. Understanding the checkpoint blockade in lung cancer immunotherapy.
Dal Bello MG; Alama A; Coco S; Vanni I; Grossi F
Drug Discov Today; 2017 Aug; 22(8):1266-1273. PubMed ID: 28600190
[TBL] [Abstract][Full Text] [Related]
94. Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling.
Rice SJ; Liu X; Zhang J; Jia B; Zheng H; Belani CP
Lung Cancer; 2019 May; 131():58-61. PubMed ID: 31027698
[TBL] [Abstract][Full Text] [Related]
95. Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients.
Germain C; Devi-Marulkar P; Knockaert S; Biton J; Kaplon H; Letaïef L; Goc J; Seguin-Givelet A; Gossot D; Girard N; Validire P; Lefèvre M; Damotte D; Alifano M; Lemoine FM; Steele KE; Teillaud JL; Hammond SA; Dieu-Nosjean MC
Front Immunol; 2021; 12():626776. PubMed ID: 33763071
[TBL] [Abstract][Full Text] [Related]
96. Prognostic value of CD4+ lymphocytes in pleural cavity of patients with non-small cell lung cancer.
Takahashi K; Saito S; Kamamura Y; Katakawa M; Monden Y
Thorax; 2001 Aug; 56(8):639-42. PubMed ID: 11462067
[TBL] [Abstract][Full Text] [Related]
97. [Tumor metastasis in patients with non-small cell lung cancer is inversely correlated with the number of tumor-infiltrating CD8
Huang Z; Su W; Han Z; Yin J; Zhang Y; Li X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Mar; 35(3):266-270. PubMed ID: 31030721
[TBL] [Abstract][Full Text] [Related]
98. Highlights on immune checkpoint inhibitors in non-small cell lung cancer.
Shen M; Ren X
Tumour Biol; 2017 Mar; 39(3):1010428317695013. PubMed ID: 28349816
[TBL] [Abstract][Full Text] [Related]
99. Prognostic value of peripheral naive CD8
Zhao X; Zhang Y; Gao Z; Han Y
Future Oncol; 2022 Jan; 18(1):55-65. PubMed ID: 34608815
[No Abstract] [Full Text] [Related]
100. The Distribution of Human Stem Cell-like Memory T Cell in Lung Cancer.
Hong H; Gu Y; Sheng SY; Lu CG; Zou JY; Wu CY
J Immunother; 2016; 39(6):233-40. PubMed ID: 27244531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
